Madrigal Solidifies Presumed NASH Lead With 52-Week Data

 
• By Joseph Haas

Full-year findings for resmetirom reported at EASL confirm 16-week data in non-alcoholic steatohepatitis presented in 2020. Analysts say these data continue to de-risk the drug, but more important readouts await.

Madrigal office
Madrigal continues to build a solid data rationale behind resmetirom • Source: Madrigal Pharmaceuticals

More from Clinical Trials

More from R&D